I‐Wei Ho

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Chung‐Pin Li · 4 shared papers, 2026 · strength 1.01
   • Paper Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancr… DOI 10.1016/j.ijrobp.2026.09.005↗
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
   • Paper Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective mul… DOI 10.1016/j.jfma.2026.04.039↗
2. Yung‐Yeh Su · 3 shared papers, 2026 · strength 0.75
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
   • Paper Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective mul… DOI 10.1016/j.jfma.2026.04.039↗
   • Paper Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcin… DOI 10.1016/j.jfma.2026.05.008↗
3. Tai‐Jan Chiu · 3 shared papers, 2026 · strength 0.75
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
   • Paper Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective mul… DOI 10.1016/j.jfma.2026.04.039↗
   • Paper Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcin… DOI 10.1016/j.jfma.2026.05.008↗
4. Li‐Yuan Bai · 3 shared papers, 2026 · strength 0.75
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
   • Paper Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective mul… DOI 10.1016/j.jfma.2026.04.039↗
   • Paper Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcin… DOI 10.1016/j.jfma.2026.05.008↗
5. Nai‐Jung Chiang · 2 shared papers, 2026 · strength 0.51
   • Paper Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancr… DOI 10.1016/j.ijrobp.2026.09.005↗
   • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
6. Wen‐Chi Chou · 2 shared papers, 2026 · strength 0.50
   • Paper Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective mul… DOI 10.1016/j.jfma.2026.04.039↗
   • Paper Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcin… DOI 10.1016/j.jfma.2026.05.008↗
7. Hsiu-Tzu Wang · 2 shared papers, 2026 · strength 0.50
   • Paper Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective mul… DOI 10.1016/j.jfma.2026.04.039↗
   • Paper Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcin… DOI 10.1016/j.jfma.2026.05.008↗
8. Shih‐Hung Yang · 2 shared papers, 2026 · strength 0.50
   • Paper Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective mul… DOI 10.1016/j.jfma.2026.04.039↗
   • Paper Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcin… DOI 10.1016/j.jfma.2026.05.008↗
9. Keng-Li Lan · 1 shared paper, 2026 · strength 0.26
   • Paper Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancr… DOI 10.1016/j.ijrobp.2026.09.005↗
10. Yi‐Ming Shyr · 1 shared paper, 2026 · strength 0.26
    • Paper Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancr… DOI 10.1016/j.ijrobp.2026.09.005↗
11. I‐Chun Lai · 1 shared paper, 2026 · strength 0.26
    • Paper Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancr… DOI 10.1016/j.ijrobp.2026.09.005↗
12. Yuan‐Hung Wu · 1 shared paper, 2026 · strength 0.26
    • Paper Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancr… DOI 10.1016/j.ijrobp.2026.09.005↗
13. Jen‐Shi Chen · 1 shared paper, 2026 · strength 0.25
    • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
14. Kun‐Ming Rau · 1 shared paper, 2026 · strength 0.25
    • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
15. Li‐Tzong Chen · 1 shared paper, 2026 · strength 0.25
    • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
16. Yao‐Yu Hsieh · 1 shared paper, 2026 · strength 0.25
    • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗
17. Yan‐Shen Shan · 1 shared paper, 2026 · strength 0.25
    • Paper SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TC… DOI 10.1016/j.ejca.2026.116229↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.